化合物 STAT3-IN-10|T60765|TargetMol

STAT3-IN-10

￥10600 25mg 起订

￥13800 50mg 起订

￥17500 100mg 起订

上海更新日期：2025-11-17

TargetMol中国（陶术生物）

VIP2年

联系人：邵小姐

手机：15002134094 拨打

邮箱：marketing@targetmol.cn

产品详情:

中文名称：: 化合物 STAT3-IN-10

英文名称：: STAT3-IN-10

CAS号：: 2499491-04-0

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

产品类别：: 抑制剂

货号：: T60765

Product Introduction

Bioactivity

名称	STAT3-IN-10
描述	STAT3-IN-10 (A11) is an inhibitor of STAT3 that directly binds to STAT3 SH2 domain, inhibits tumor cell growth and induces apoptosis in cancer cells (IC 50 = 5.18 μM) [1].
体外活性	STAT3-IN-10 (A11) (48 h) shows IC 50 values of 0.67, 0.77, 1.24 μM against MDA-MB-231, MDA-MB-468, HepG2 cells, respectively [1]. STAT3-IN-10 (A11) directly binds to the STAT3 SH2 domain [1]. STAT3-IN-10 (A11) (0-3 μM, 24 h) inhibits the phosphorylation of STAT3 and its downstream target proteins and has a good selectivity against the tumor suppressor STAT1 [1]. STAT3-IN-10 (A11) (0-4 μM, 24 h) induces apoptosis in cancer cells [1]. STAT3-IN-10 (A11) (0-4 μM, 24 h) dose-dependently causes a significant S phase arrest in MDA-MB-231 cells [1]. Cell Viability Assay [1] Cell Line: Breast cancer cell lines: MDA-MB-231 and MDA-MB-468; human liver carcinoma cell line: HepG2. Concentration: Incubation Time: 48 h, re-incubated for 4 h (MDA-MB-468, MDA-MB-231) and 1h (HepG2). Result: Showed IC 50 values of 0.67, 0.77, 1.24 μM against MDA-MB-231, MDA-MB-468, HepG2 cells, respectively. Western Blot Analysis [1] Cell Line: MDA-MB-231. Concentration: 0, 0.75, 1.5 and 3.0 μM. Incubation Time: 24 h. Result: Decreased the STAT3-Y705 phosphorylation without affecting the total amount of STAT3 protein and decreased the expression of STAT3 target genes, including C-Myc and Cyclin D1 in a dose-dependent manner. Had little impact on the level of STAT1 and its phosphorylation on Tyr701. Apoptosis Analysis [1] Cell Line: MDA-MB-231. Concentration: 0, 1, 2, and 4 μM. Incubation Time: 24 h. Result: Induced the apoptosis in MDA-MB-231 cells in a concentration-dependent manner Cell Cycle Analysis [1] Cell Line: MDA-MB-231. Concentration: 0, 1, 2, and 4 μM. Incubation Time: 24 h. Result: Could dose-dependently cause a significant S phase arrest in MDA-MB-231 cells
体内活性	STAT3-IN-10 (A11) (5 and 10 mg/kg; IP; once a day, 21 days) inhibits the growth of human xenograft tumor in vivo [1]. Animal Model: Five weeks old female BALB/c nude mice (16–18g) bearing inoculation of human breast cancer cells MDA-MB-231 [1]. Dosage: 5 and 10 mg/kg Administration: IP, once a day, 21 days Result: Inhibited the growth of human xenograft tumor in vivo without apparent body-weight loss for treated mice and inhibited the levels of p-STAT3 in tumor tissues.
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
相关产品	Sodium citrate \| L-Methionine \| Gefitinib \| Cysteamine hydrochloride \| Alginic acid \| Metronidazole \| Dextran sulfate sodium salt (MW 5000) \| Citric Acid Triammonium \| Stavudine \| Cystamine dihydrochloride \| L-Ascorbic acid sodium salt \| Sodium 4-phenylbutyrate

STAT3-IN-10|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(13年)
注册资本	589.8595万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	中间体,天然产物,生物化工,化学试剂,生物技术服务

化合物 STAT3-IN-10相关厂家报价

化合物 NLRP3-IN-10—2641826-39-1
湖北魏氏化学试剂股份有限公司 VIP
2025-09-18
询价

化合物 SIK-IN-4
奥夫仑医药（四川）有限公司 VIP
2025-11-27
询价

化合物 IL-2-IN-1
康迈迪森（北京）医药科技有限公司 VIP
2025-10-16
￥1000

内容声明